This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.
Histologically confirmed diagnosis of prostate adenocarcinoma Age ≥18 years Receiving curative intent radiotherapy for prostate cancer (Note: post-operative radiotherapy [i.e., "adjuvant" or "salvage radiotherapy subsequent to prostatectomy] is allowed.) Subjects will be enrolled within two weeks prior to and two weeks after the final fraction of radiotherapy.
Receiving androgen deprivation therapy (ADT) for a duration of ≥3 consecutive months as follows:
GnRH agonist or antagonist (medical castration), with or without an anti-androgen (i.e., bicalutamide, flutamide, nilutamide, etc.), OR Bilateral orchiectomy (surgical castration) Technology requirement: candidates must have access to the internet Able to understand and willing to sign a written informed consent document. Able to speak and understand English, in the opinion of the treating physician.
Exclusion Criteria:
Significant concurrent medical or psychiatric condition that would interfere with the patient's ability to abide by the study protocol or cooperate fully with the protocol requirements, including completion of survey and assessment
